ACADIA PHARMACEUTICALS INC: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp has disclosed a stake exceeding 5% in ACADIA Pharmaceuticals Inc. through a Schedule 13G filing with the SEC (accession 0000093751-26-000603). The exact share count and percentage were not specified in the filing headline. The disclosure signals that State Street, one of the largest institutional asset managers, holds a significant passive position in the biopharmaceutical company. Investors will watch for further detail on the precise size of the stake and any subsequent 13F or amendment filings that clarify State Street's holdings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
STATE STREET CORP, ACADIA PHARMACEUTICALS INC